Ari­ad’s briga­tinib scores 15.6 month PFS rate; Neurim­mune backs ALS spin­out

Ari­ad Phar­ma­ceu­ti­cals is re­port­ing that its ALK in­hibitor briga­tinib scored a 55% ob­jec­tive re­sponse rate in among pa­tients tak­ing 180 mg. In this same arm …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER